Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 2008

View Archived Issues

HSV-2 vaccine dl5-29 effective in HSV-1 seropositive guinea pigs

Recent patents disclose new anticancer agents

G-CSF-induced neuroprotection in mouse models of ALS

Avir commences phase I study for intranasal pandemic influenza vaccine deltaFLU

Proellex reduces pain in phase II clinical trial in moderate to severe endometriosis

GlobeImmune collaborates with the NIH to develop cancer therapeutics

Targeting CaMKK2 may be useful for the treatment of obesity and diabetes

Novartis enters strategic partnership with Lonza to accelerate its biologics pipeline

Study shows bioequivalence between Insmed's INS-19 and Neupogen

Novel analgesic agents described in recent patent literature

Proteolix initiates dosing in phase Ib clinical trial of proteasome inhibitor carfilzomib

Promising preclinical results with STF-62247 in treating renal cell carcinoma

DSMB recommends discontinuation of vaccinations in phase III TRIST study of TroVax

Recent Exelixis and Nippon Zoki patents report new treatment options for metabolic disorders

Pharming reports positive results from open-label studies of Rhucin in HAE

Napo reports results from phase IIa and IIb trials of crofelemer in D-IBS

NeurogesX initiates phase I clinical trial of NGX-1998 for neuropathic pain

Nile Therapeutics initiates dosing in phase IIa clinical study of CD-NP in heart failure

Alcon terminates development of anecortave acetate in AMD

Actelion and GSK collaborate on almorexant in sleep disorders

Tredaptive approved in E.U. for dyslipidemia and primary hypercholesterolemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...